Авторы
Сероус Ю.В.1, Файбушевич А.Г.1, Гительзон Е.А.1, Максимкин Д.А.1, Баранович В.Ю.1, Гительзон Д.Г.2, Веретник Г.И.1
1 ФГБОУ ВО «Российский университет дружбы народов», Москва
2 ФГБУ «Национальный медицинский исследовательский центр гематологии», Москва
Аннотация
Заболевания артерий нижних конечностей крайне широко распространены у пациентов, страдающих сахарным диабетом. Продолжительность сахарного диабета и концентрация глюкозы в крови коррелируют с выраженностью атеросклеротического поражения артерий нижних конечностей, критической ишемией, количеством ампутаций и летальными исходами. Также гипергликемия у больных сахарным диабетом приводит к увеличению частоты тромботических осложнений во всех сосудистых бассейнах. Своевременная диагностика и лечение поражения артерий нижних конечностей у больных сахарным диабетом позволяет значительно улучшить качество и продолжительность жизни.
Ключевые слова: заболевания артерий нижних конечностей, сахарный диабет, атеросклероз, заболевания периферических артерий, реваскуляризация.
Список литературы
1. IDF Diabetes Atlas, 9th edition. Brussels: International Diabetes Federation; 2019; [URL].
2. Plesen KKW, Gyldenkerne C, Thim T, Thomsen RW, Maeng M. Perioheral artery disease, lower limb revascularization, and amputation in diabetes patients with and without coronary artery disease: a cohort study from the Western Denmark heart Registry. BMJ Open Diabetes Res Care. 2021; 9(1): e001803. doi:10.1136/bmjdrc-2020-001803.
3. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей. Ассоциация сердечно-сосудистых хирургов России, Российское общество ангиологов и сосудистых хирургов, Российское общество хирургов, Российское кардиологическое общество, Российская ассоциация эндокринологов. — М., 2019. — 89 с.
4. Agboghoroma OF, Akemokwe FM, Puepet FH / Peripheral arterial disease and its correlates in patients with type 2 diabetes mellitus in a teaching hospital in northern Nigeria: a cross-sectional study. BMC Cardiovasc Disord. 2020; 20: 102. doi:10.1186/s12872-020-01395-3.
5. Berger JS, Newman JD. Overview of peripheral artery disease in patients with diabetes mellitus. UpToDate. 2021.
6. Харазов А.Ф., Каляев А.О., Исаев А.А. Распространенность симптомной ишемии нижних конечностей в Российской Федерации // Хирургия. Журнал им. Н.И. Пирогова. — 2016.– №7. — С.58-61. doi: 10.17116/hirurgia2016758-61.
7. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002; 25(5): 894.
8. Cardoso CRL, Melo JV, Salles GC, Leite NC, Salles GF. Prognostic impact of the ankle-brachial index on the development of micro- and macrovascular complication in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Diabetologia. 2018; 61: 2266-2276.
9. Vrsalovic M, Vucur K, Vrsalovic Presecki A, Fabijanic D, Milosevic M. Impact of diabetes on mortality in peripheral artery disease: a meta-analysis. Clin Cardiol. 2017; 40(5): 287-291. doi:10.1002/clc.22657.
10. Sala LL, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. European Journal of Preventive Cardiology. 2019; 26(2): 15-24. doi:10.1177/2047487319878373.
11. Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int. J. Mol. Sci. 2020; 21(5): 1835. doi:10.3390/ijms21051835.
12. Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes Dyslipidemia. Diabetes Ther. 2016; 7(2): 203-219. doi: 10.1007/s13300-016-0167-x.
13. Гаранина Е.Е., Мартынова Е.В., Иванов К.Я., Ризванов А.А., Хайбуллина С.Ф. Инфламмасомы: роль в патогенезе заболеваний и терапевтический потенциал // Учен. зап. Казан. ун-та. Сер. Естеств. науки. — 2020. — Т.162. — Кн.1. — С.80-111. doi: 10.26907/2542-064X.2020.1.80-111.
14. Kaur R, Kaur M. Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018; 17: 121-138. doi: 10.1186/s12933-018-0763-3.
15. Ghoshal K, Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Sci World J. 2014: 1-16.
16. La Sala L, Mrakic-Sposta S, Tagliabue, et al. Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high risk of developing diabetes and in drug-naïve T2D. Cardiovasc Diabetol. 2019; 18: 18-18.
17. Jimenez-Lucena R, Rangel-Zuniga OA, Alcala-Diaz JF, et al. Circulating miRNAs as predictive biomarkers of type 2 diabetes mellitus development in coronary heart disease patients from the CORDIOPREV study. Mol Ther Nucleic Acids. 2018; 12: 146-157.
18. Vasu S, Kumano K, Darden CM, Rahman I, Lewrence MC, Naziruddin B. MicroRNA signatures as future biomarkers for diagnosis of diabetes states. Cells. 2019; 8: 1533.
19. Barutta F, Bellini S, Mastrocola R, Bruno G, Gruden G. Micro RNA and microvascular complications of diabetes. Int. J. Endocrinol. 2018: 6890501.
20. American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41(1): S105-18.
21. Weiss NS, McClelland R, Criqui MH, Wassel CL, Kronmal R. Incidence and predictors of clinical peripheral artery disease in asymptomatic persons with a low ankle–brachial index. J Med Screen. 2018. doi: 10.1177/0969141318773782.
22. Davies JH, Kenkre J, Williams EM. Current utility of the ankle–brachial index (ABI) in general practice: implications for its use in cardiovascular disease screening. BMC Fam Pract. 2014; 15: 69.
23. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA / ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology. American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; 69(11): e71–e126.
24. Mitchell E, Eidt J, Mills J. Waltham, MA: UpToDate; 2018. Noninvasive diagnosis of arterial disease.
25. Nativel M, Potier L, Alexandre L, et al. Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. Cardiovasc Diabetol. 2018; 17: 138. doi: 10.1186/s12933-018-0781-1.
26. Mohammedi K, Woodward M, Hirakawa Y, et al. Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes. Diabetes Care. 2016; 39(10I): 1796-803.
27. Hasan R, Firwana B, Elraiyah T, et al. A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. J Vasc Surg. 2016; 63(2-1): 22S–28S.e21-22.
28. Althouse AD, Abbott JD, Sutton-Tyrrell K, et al. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care. 2013; 36(101): 3269-75.
29. Mary A, Hartemann A, Liabeuf S, et al. Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. Cardiovasc Diabetol. 2017; 16(11): 24.
30. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(191): 1834-44.
31. Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornoe K, Pratley RE. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. Diabetes Care. 2018; 41: 2229-35.
32. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377(131): 1228-39.
33. Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018; 41(11): e4-5.
34. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9I): 763-816.
35. Kumbhani DJ, Steg PG, Cannon CP, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014; 35(41I): 2864-72.
36. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500I): 1849-61.
37. Karatasakis A, Danek BA, Karacsonyi J, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017; 6(12I): e006910.
38. Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018; 137(4I): 338-50.
39. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo-controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840.
40. Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017; 76(1I): 32-40.
41. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (cilostazol: a study in long-term effects). J Vasc Surg. 2008; 47(2I): 330-6.
42. De Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev. 2008. doi: 10.1002/14651858.CD001368.pub3.
43. He X, Hu X, Ma X, et al. Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017; 16(1I): 77.
44. Gorenoi V, Brehm MU, Koch A, Hagen A. Growth factors for angiogenesis in peripheral arterial disease. Cochrane Database Syst Rev. 2017; 6: CD011741.
45. Rigato M, Monami M, Fadini GP. Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies. Circ Res. 2017; 120(8I): 1326-40.
46. Darling JD, Bodewes TCF, Deery SE, Guzman RJ, Wyers MC, Hamdan AD, Verhagen HJ, Schermerhorn ML. Outcomes after first-time lower extremity revascularization for chronic limb-threatening ischemia between patients with and without diabetes. J Vasc Surg. 2018; 67(4I): 1159-69.
47. Liang P, Soden PA, Zettervall SL, Shean KE, Deery SE, Guzman RJ, Hamdan AD, Schermerhorn ML. Treatment outcomes in diabetic patients with chronic limb-threatening ischemia. J Vasc Surg. 2018; 68(2I): 487-94.
48. Kavanagh CM, Heidenreich MJ, Albright JJ, Aziz A. Hybrid external iliac selective endarterectomy surgical technique and outcomes. J Vasc Surg. 2016; 64(5I): 1327-34.
49. Grimme FA, Goverde PC, Verbruggen PJ, Zeebregts CJ, Reijnen MM. Editor’s choice-first results of the covered endovascular reconstruction of the aortic bifurcation (CERAB) technique for aortoiliac occlusive disease. Eur J Vasc Endovasc Surg. 2015; 50(5I): 638-47.
50. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012; 19(1I): 1-9.
